Thread: Michael Fox Partners to Assess Clinical Development of Nilotinib in Parkinson's
View Single Post
Old 07-12-2016, 12:39 PM
zanpar321 zanpar321 is offline
Member
  
Join Date: Feb 2014
Posts: 365
10 yr Member
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
Default Michael Fox Partners to Assess Clinical Development of Nilotinib in Parkinson's
This is great news folks!

Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s

Posted by Maggie McGuire Kuhl, July 12, 2016

A promising therapy that may slow or stop Parkinson’s progression is moving forward. Today The Michael J. Fox Foundation (MJFF), the Van Andel Research Institute (VARI) in Michigan and the Cure Parkinson’s Trust (CPT) in the United Kingdom announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib.

The program includes the goal of planning of a double-blind, placebo-controlled clinical trial of nilotinib, which MJFF hopes can begin in 2017.

Parkinson's Disease | Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s
Last edited by zanpar321; 07-12-2016 at 02:39 PM. Reason: Adding new text
zanpar321 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
eds195 (07-12-2016), imark3000 (07-12-2016), jeffreyn (07-12-2016), RLSmi (07-12-2016), Tupelo3 (07-12-2016)